[Renal cancer biomarkers. What is justified?].
Renal carcinoma biomarkers are of potential interest for the diagnosis of renal tumor subtypes and prediction of prognosis or reponses to targeted therapies. Due to the identification of novel renal tumor subtypes, diagnostic immunohistochemical biomarkers are of increasing importance. However, there is currently not enough clinical evidence to recommend prognostic or predictive biomarkers in routine pathology. Therapeutic decisions are still based on correct tumor classification, tumor differentiation grade, and tumor stage. Recent studies have emphasized the relevance of detailed analysis of hilus fat tissue for a correct pT-category. This review summarizes recent developments in renal cancer biomarker research.
Institut für Klinische Pathologie, UniversitätsSpital Zürich, Schmelzbergstr. 12, 8091 Zürich. holger.moch@usz.ch
H
H
Moch
D000273:Adipose Tissue / Q000473:pathology; D014408:Biomarkers, Tumor / Q000032:analysis*; D002292:Carcinoma, Renal Cell / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology* / Q000601:surgery; D006801:Humans; D007668:Kidney / Q000473:pathology; D007680:Kidney Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology* / Q000601:surgery; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D009392:Nephrectomy; D011379:Prognosis
D014408:Biomarkers, Tumor